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Background
The use of single-dose primaquine to block transmission
of Plasmodium falciparum malaria is complicated by var-
iation in glucose-6-phosphate-dehydrogenase (G6PD)
activity and potentially cytochrome P450 2D6 (CYP2D6).
G6PD deficiency determines primaquine safety while the
CYP2D6 metabolizer phenotype may determine prima-
quine efficacy by influencing metabolism into active
metabolite(s). While there is evidence that the CYP2D6
metabolizer phenotype influences primaquine efficacy
against P. vivax hypnozoites, there is currently no evi-
dence for CYP2D6 in relation to its gametocytocidal
activity in P. falciparum.
Materials and methods
We used samples from a dose-finding study where Ugan-
dan children with uncomplicated malaria were rando-
mized to receive artemether-lumefantrine together with a
placebo or 0.1, 0.4 or 0.75 mg/kg primaquine. Gametocyte
carriage was determined by Pfs25 QT-NASBA on nucleic
acids from 50 μL blood samples that were subsequently
used for CYP2D6 assays. Using the QuantStudio 12K Flex
system and 32SNP OpenArray as well as copy number
variation (CNV) assays, CYP2D6 genotypes were deter-
mined for the available DNA samples.
Results
247 out of 468 individuals included in the trial were suc-
cessfully genotyped for CYP2D6. CYP2D6 phenotypes
were predicted from the genotypes with the classical
method, yielding phenotypes for all but 13% of genotyped
individuals. The number of poor metabolizers (PM) and
ultrarapid metabolizers (UM) in this Ugandan cohort was
very low (2% for both), while 25% (62/247) of the children
were intermediate metabolizers (IM). Gametocyte preva-
lence on day 7 after initiation of treatment with 0.4 mg/kg
primaquine was 7% (2/28) in extensive metabolizers (EM)
or UM compared to 38% (3/8) in IM and 100% (1/1) in
PM (P = 0.009). The same pattern was not present in the
other treatment arms.
Conclusions
The number of PM is low in our study population and
does not allow a firm conclusion on its impact on gameto-
cyte clearance following primaquine. IM had longer per-
sisting gametocytes after receiving 0.4mg/kg primaquine
suggesting that the transmission-blocking effect of low-
dose primaquine may be influenced by CYP2D6 activity.
Larger studies that include mosquito infectivity outcomes
are needed to firmly establish whether CYP2D6 variations
impact the utility of primaquine for P. falciparum trans-
mission reducing activities.
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